Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-799-4
CAS number: 2536-05-2
The principal route of concern for human exposure is via inhalation. Reliable repeated dose inhalation toxicity data is available for the source substances 4,4’-MDI and pMDI (Hoymann et al. 1995., Reuzel et al. 1994) and are read across to the target substance. Since all substances of the MDI category contain significant levels of monomeric MDI, 4,4’-MDI represents a worst case with the highest levels of reactive free NCO groups. For the repeated dose toxicity endpoint, the observation in the respiratory tract, especially the lung noted in both source substances is consistent with the hypothesized MoA. As a MDI substance enters the lung, NCO groups react with biological nucleophiles at the MDI/lung fluid interface to form MDI-conjugates. Formation of these MDI-adducts depletes protective nucleophiles in the lung and results in pulmonary irritation and inflammatory cell influx. As these acute effects become chronic this result in histopathological changes characterized by interstitial fibrosis, hyperplasia of the alveolar epithelium and a low incidence of bronchiolo-alveolar adenoma, the latter occurring in the high exposure groups of both chronic source substance studies (Hoymann et al. 1995., Reuzel et al. 1994). The available animal toxicity data shows that the content of bioaccessible NCO groups is the driving factor of lung toxicity after repeated inhalation with a negligible contribution from the higher molecular weight components and a lack of any systemic exposure or toxicity. This supports the conclusion that data generated for 4,4’-MDI and pMDI can be used as a worst-case source for read across to the target substance, which has in common with the source substances a high content of bioaccessible monomeric MDI. Accordingly, the CLP classification (STOT RE 2, H373) for 4,4’-MDI and pMDI is adopted for all other substances in the MDI category, including the target substance 2,2’-MDI, which is in line with the current legal classification of 2,2’-MDI in Europe.
In summary, the available data on the endpoint repeated dose toxicity are considered adequate and sufficient for classification and labelling. To support the weight of evidence additional testing is planned. It is considered to perform a sub-chronic inhalation toxicity study (OECD 413) with boundary substance 4,4’-MDI/DPG/HMWP. Additional, combined Repeated Dose Toxicity studies with Reproductive/ developmental Toxicity Screening tests (OECD 422) will be performed on 9 substances representing all sub-groups and key structural/chemical characteristics (see Test Proposal Summary attached in Chapter 13). These studies will confirm the proposed MoA on repeated dose toxicity or identify substances that may require additional testing.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Tato webová stránka používá cookies, aby se vám naše stránky používaly co nejlépe.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again